Immune Response Affecting Drug Patents (Class 514/885)
  • Patent number: 10249827
    Abstract: The present invention relates to compounds of formula (I), which are characterized in that they substituted by benzimidazo[1,2-a]benzimidazo-5-yl and/or benzimidazo[1,2-a]benzimidazo-2,5-ylene groups and in that at least one of the substituents B1, B2, B3, B4, B5, B6, B7 and B8 represents N; a process for their production and their use in electronic devices, especially electroluminescent devices. When used as host material for phosphorescent emitters in electroluminescent devices, the compounds of formula I may provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: April 2, 2019
    Assignee: UDC Ireland Limited
    Inventors: Annemarie Wolleb, Thomas Schaefer, Heinz Wolleb, Ute Heinemeyer, Nicolle Langer, Christian Lennartz, Gerhard Wagenblast, Soichi Watanabe, Flavio Luiz Benedito, Heinz Hottinger, Oliver Dosenbach
  • Patent number: 9035030
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: May 19, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 8945545
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: February 3, 2015
    Assignee: AbbVie Inc.
    Inventors: Joaquin Mario Valdes, Susan K. Paulson
  • Patent number: 8916525
    Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: December 23, 2014
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, The Catholic University of Korea
    Inventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Jin Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
  • Patent number: 8889185
    Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: November 18, 2014
    Assignee: Veloxis Pharmaceuticals A/S
    Inventors: Per Holm, Tomas Norling
  • Patent number: 8889186
    Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: November 18, 2014
    Assignee: Veloxis Pharmaceuticals A/S
    Inventors: Per Holm, Tomas Norling
  • Patent number: 8865174
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 8865684
    Abstract: The invention is directed to a method of administering hydrogen sulfide (H2S) slowly and sustainably to an individual in need thereof comprising administering an effective amount of a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: October 21, 2014
    Assignee: National University of Singapore
    Inventors: Philip Keith Moore, Choon-Hong Tan, Ling Li, Yan Yi Guan
  • Patent number: 8846757
    Abstract: Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are compounds according to Formulas I-IV, pharmaceutical compositions, unit dosage forms, and food or feed supplements containing such compounds.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: September 30, 2014
    Assignees: The Trustees of Columbia University in the City of New York, The Research Foundation of The City University of New York
    Inventors: Jeanine D'Armiento, Kurt Reynertson, Edward Kennelly, Alison Wallace
  • Patent number: 8815948
    Abstract: An alternative method of delivery of homeopathic medicines by targeting delivery to the MALT's, especially of the intestinal tract and in high volumes.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: August 26, 2014
    Inventors: Char Tara Albert, Floyd E. Taub
  • Patent number: 8796333
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: August 5, 2014
    Assignee: Abbott Laboratories
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Patent number: 8795674
    Abstract: The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: August 5, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Arya Biragyn, Kouji Matsushima, Dolgor Bataar
  • Patent number: 8778992
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: July 15, 2014
    Assignee: Abbott Laboratories
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Patent number: 8728747
    Abstract: Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: May 20, 2014
    Assignee: University of Louisville Research Foundation, Inc.
    Inventor: Haval Shirwan
  • Patent number: 8722700
    Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: May 13, 2014
    Assignee: Wyeth LLC
    Inventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
  • Patent number: 8703141
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as Crohn's disease.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: April 22, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 8685998
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: April 1, 2014
    Assignee: Veloxis Pharmaceuticals A/S
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 8685728
    Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: April 1, 2014
    Assignee: Rutgers The State University of New Jersey
    Inventors: Yufang Shi, Guangwen Ren, Liying Zhang
  • Patent number: 8673887
    Abstract: The present invention relates to compounds and methods which may be useful for the treatment of inflammatory bowel disease, Crohn's disease and colitis.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: March 18, 2014
    Assignee: Reveragen Biopharma, Inc
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Patent number: 8673281
    Abstract: A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: March 18, 2014
    Assignee: BioCis Pharma Oy
    Inventors: Lasse Leino, Jarmo Laihia
  • Patent number: 8673280
    Abstract: A pharmaceutically acceptable agent able to acidify the cell cytoplasm for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: March 18, 2014
    Assignee: BioCis Pharma Oy
    Inventors: Lasse Leino, Jarmo Laihia
  • Patent number: 8668908
    Abstract: Extract fractions of Dioscorea sp. and methods of preparing the extract fractions are disclosed. The extract fractions enhance the proliferation and differentiation of bone marrow cells. Also described are a method for treatment of osteoporosis and a method for alleviation of side effects caused by chemotherapy by using the extract fractions of Dioscorea sp.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: March 11, 2014
    Assignee: National Yang-Ming University
    Inventor: Rong-Tsun Wu
  • Patent number: 8664239
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: March 4, 2014
    Assignee: Veloxis Pharmaceuticals A/S
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 8637084
    Abstract: It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising: step (a) of selectively reducing KLRG1-positive immunocytes in the peripheral blood of a living individual with epithelial cancer ex vivo, which is positive for a cancer-specific membrane antigen expressed in epithelial cancer cells and positive for a KLRG1 ligand; and step (b) of administering, to the living individual, a therapeutic agent for cancer comprising an antibody reacting with the cancer-specific membrane antigen expressed in epithelial cancer cells and having antibody-dependent cell cytotoxicity.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: January 28, 2014
    Assignees: Asahi Kasei Medical Co., Ltd., National Cancer Center
    Inventors: Mikitomo Yasutake, Kasumi Ninomiya, Junichi Honda, Atsushi Ochiai, Chisako Yamauchi
  • Patent number: 8617598
    Abstract: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: December 31, 2013
    Assignee: Novartis AG
    Inventors: Barbara Haeberlin, Andrea Kramer, Silvia Heuerding
  • Patent number: 8592487
    Abstract: This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a human immunodeficiency virus (HIV) protease inhibitor, such as darunavir.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: November 26, 2013
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 8575198
    Abstract: The present disclosure provides methods for manufacturing or producing glatiramer acetate having a Mp of 5000-9000 Da.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: November 5, 2013
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Mani S. Iyer, Harper Kaminski
  • Patent number: 8568723
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 29, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Patent number: 8557239
    Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 15, 2013
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Joaquin Mario Valdes, Elliot K. Chartash, William T. Barchuk, Susan K. Paulson, Kenneth B. Gordon, Walid M. Awni, Yanjun Bao, William G. Glass, Yihua Gu, Tom C. Harris, Martin Kaul, Parvez M. Mulani, Peter Noertersheuser, Martin M. Okun
  • Patent number: 8541546
    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: September 24, 2013
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8529904
    Abstract: A peptide comprising the amino acid sequence RMFPNAPYL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: September 10, 2013
    Assignee: Ganymed Pharmaceuticals AG
    Inventors: Hans Josef Stauss, Liquan Gao
  • Patent number: 8518401
    Abstract: A therapeutic agent for an inflammatory disease comprising an antibody or a CX3CR1 antagonist that inhibits an interaction of fractalkine and CX3CR1 is provided.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: August 27, 2013
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshikazu Kuboi, Toshio Imai, Miyuki Nishimura, Keiko Mizuno
  • Patent number: 8486993
    Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: July 16, 2013
    Assignee: Veloxis Pharmaceuticals A/S
    Inventor: Per Holm
  • Patent number: 8455464
    Abstract: A composition for the treatment of adhesions that are formed as a result of an inflammatory response comprising an aqueous formulation containing the polysaccharide dextrin in an effective amount. The invention also discloses a method of treating adhesions that are formed as a result of an inflammatory response.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: June 4, 2013
    Assignee: Innovata Limited
    Inventor: Susan Conroy
  • Patent number: 8455539
    Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: June 4, 2013
    Assignee: Wyeth LLC
    Inventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
  • Patent number: 8455445
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: June 4, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Patent number: 8449888
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: May 28, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 8445272
    Abstract: This invention relates to galactosylceramide compounds.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: May 21, 2013
    Assignees: The Scripps Research Institute, The University of Chicago, Brigham Young University
    Inventors: Paul B. Savage, Albert Bendelac, Luc Teyton
  • Patent number: 8440199
    Abstract: The current invention provides a method for mobilizing endothelial progenitor cells (EPC) and/or mesenchymal stem cells (MSC) in a patient, wherein the method comprises the steps of (i) administering a vascular endothelial growth factor receptor (VEGFR) agonist to the patient; and (ii) administering an antagonist of CXCR4 to the patient. Also provided are uses of EPC and MSC harvested using the methods of the invention.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: May 14, 2013
    Assignee: Imperial Innovations Limited
    Inventors: Sara Margaret Rankin, Simon Charles Pitchford
  • Patent number: 8425897
    Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: April 23, 2013
    Assignee: Immutep S.A.
    Inventors: Karin Jooss, Betty Li, Frederic Triebel
  • Patent number: 8399416
    Abstract: The present invention is for an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 9 and using the peptide for treating asthma by reducing cytotoxicity of eosinophil derived toxins in bronchial epithelial cells of the subject suffers from asthma. The method comprises preparing a pharmaceutical composition having the peptide of SEQ ID NO: 9 and administering an effective amount of the composition to the subject.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: March 19, 2013
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Tan-chi Fan, Shu-Chuan Lin
  • Patent number: 8383124
    Abstract: Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: February 26, 2013
    Assignee: Children's Hospital Medical Center
    Inventor: Yi Zheng
  • Patent number: 8361512
    Abstract: Provided are methods and compositions for increasing CD4+ cell count in mammals, preferably by at least 25%, while undergoing treatment for various conditions whose treatment can have detrimental effects on immune system function. Such conditions include, but are not limited to, HIV infection, cancer, and hepatitis. The compositions include alpha lipoic acid; acetyl L-carnitine; N-acetyl-cysteine; zinc; selenium; vitamin C; bioflavinoid complex; vitamin E; optionally one or more antioxidants selected from co-enzyme Q10 and glutathione; and one or more vitamins or minerals selected from beta-carotene, vitamin A, vitamin B1, vitamin B2, vitamin B6, niacinamide, calcium pantothenate, folic acid, vitamin B12, copper, manganese, chromium, and molybdenum.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 29, 2013
    Assignee: K-PAX Vitamins, Inc.
    Inventor: Jon D. Kaiser
  • Patent number: 8318177
    Abstract: The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: November 27, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Larry W. Kwak, Bira Arya
  • Patent number: 8313738
    Abstract: A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: November 20, 2012
    Assignee: BioCis Pharma Oy
    Inventors: Lasse Leino, Jarmo Laihia
  • Patent number: 8299116
    Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: October 30, 2012
    Assignee: Wyeth LLC
    Inventors: Joseph T Rubino, Victoria Siskavich, Maureen M Harrison, Pooja Gandhi
  • Patent number: 8287923
    Abstract: Green tea polyphenol compositions and methods of their use are provided. Certain aspects provide methods for modulating expression of one or more autoantigens using the disclosed green tea polyphenol compositions. Representative green tea polyphenols include, but are not limited to (?)-epigallocatechin-3-gallate. Other aspects provide methods for treating autoimmune disease.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: October 16, 2012
    Assignee: Medical College of Georgia Research Institute, Inc.
    Inventors: Stephen D. Hsu, Carol A. Lapp, George S. Schuster
  • Patent number: 8268331
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: September 18, 2012
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 8236794
    Abstract: A method of treating mesothelioma in a mammal, whereby a methylol-containing compound is administered to the mammal intrapleurally.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: August 7, 2012
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventor: Rolf W. Pfirrmann
  • Patent number: 8192741
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: June 5, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow